Recent share performance and what it signals for investors

Huntsman (HUN) has drawn attention after a period of solid share performance, with the stock up 0.9% over the past day, 5.1% over the past week, and 6.5% over the past month.

Over the past 3 months, the stock is up 11.6%, while the 1 year total return stands at 35.2%. Year to date, Huntsman is up 42.4%, which places recent trading action front and center for investors reviewing materials sector exposure.

At a share price of $14.51, Huntsman’s recent 1 month and year to date share price returns suggest building momentum, even though the 3 year and 5 year total shareholder returns remain weak.

If Huntsman’s move has you reassessing the chemicals space, it could be a good moment to widen your research and compare it with 20 top founder-led companies

With the stock at $14.51, trading slightly above the average analyst price target and with weak 3 and 5 year returns, should you view Huntsman as undervalued today, or is the market already accounting for its future growth prospects?

Most Popular Narrative: 1% Overvalued

Huntsman’s most followed narrative puts fair value at $14.31, slightly below the latest close at $14.51. This frames the current rally as almost fully reflected.

Cost optimization, working capital discipline, and strategic asset closures (e.g., the maleic anhydride facility in Europe) are expected to enhance free cash flow generation and support improved net margins and earnings resilience during the next macro upturn.

Want to see what sits behind that earnings rebuild story? The narrative leans heavily on revenue momentum, a sharp margin reset, and a much lower future earnings multiple.

Result: Fair Value of $14.31 (OVERVALUED)

However, this depends on tight assumptions, and setbacks in MDI pricing or prolonged weakness in construction demand could quickly undermine that fair value story.

Another angle on valuation

The analyst narrative frames Huntsman as about 1% overvalued at $14.51 versus a fair value of $14.31. Yet on a simple P/S ratio of 0.4x, the stock trades well below both the US Chemicals industry at 1.1x and peers at 1.2x, and below an estimated fair ratio of 1x. Is the market still pricing in too much earnings risk here, or is this discount exactly what you would expect for a business with recent losses and forecast slow growth?

To see how those P/S gaps translate into real valuation risk, and how they compare with other companies in the sector, See what the numbers say about this price — find out in our valuation breakdown.

Next Steps

The mix of solid recent returns and longer term weakness leaves a lot of room for interpretation. It makes sense to look at the facts yourself and move quickly while the data is fresh, then weigh 1 key reward and 2 important warning signs

Looking for more investment ideas?

If Huntsman has sharpened your focus, do not stop here. A few minutes spent scanning other opportunities now could be the difference between watching and acting.

• Target resilient income by reviewing companies in the 10 dividend fortresses and see which stocks line up with your cash flow goals.
• Spot potential mispricings early by checking the 48 high quality undervalued stocks before attention shifts and prices adjust.
• Prioritize sleep-at-night holdings with the 69 resilient stocks with low risk scores and keep your portfolio tilted toward stability.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.